Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05642325 · ClinicalTrials.gov registry record · Phase 3
Vamikibart in Participants With Uveitic Macular Edema
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 256
- Enrollment target
NCT05642325 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 256 participants.
The verdict
NCT05642325, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 256 participants
- Enrollment target
Study Summary
This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.
Interventions
- OTHER Sham
- DRUG Vamikibart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2023-03-23 |
| Est. Completion | 2025-12-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05642325
The ClinicalTrials.gov registry entry for NCT05642325 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham is the first listed.
NCT05642325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05642325 about?
NCT05642325 is a clinical study titled "Vamikibart in Participants With Uveitic Macular Edema". This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.
What is the current status of trial NCT05642325?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 256 participants. The study started on 2023-03-23. Estimated completion is 2025-12-24.
What interventions are being tested in trial NCT05642325?
The interventions under investigation include: Sham (OTHER), Vamikibart (DRUG).
Who is sponsoring clinical trial NCT05642325?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.